ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Effectiveness of clomiphene citrate on total motile sperm count and hormonal profile in men with clinical infertility.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfertility affects 15% of couples worldwide, yet evidence for empiric therapy in idiopathic male factor infertility is limited. Clomiphene citrate (CC), a selective estrogen receptor modulator that stimulates gonadotropins, is widely prescribed, but its impact on total motile sperm count (TMSC) and reproductive hormones remains uncertain. This study evaluated CC therapy and subsequent changes in TMSC and hormones in infertile men.
methodsThis single-center, retrospective cohort included 60 men ≥18 years with idiopathic infertility treated with CC between January 2022 and November 2024. The primary outcome was change in TMSC; secondary outcomes were changes in testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and 17-hydroxyprogesterone (17-OHP) before and after CC. Hormonal changes were assessed with paired t-tests; primary vs. secondary infertility with independent t-tests; and predictors of TMSC change with multivariable linear regression.
resultsSixty men (mean age 35.6±4.6 years) were treated for 12.9±6.1 months. Following CC, mean TMSC increased by 13.1 million (p=0.005), 17-OHP by 1.8 nmol/L, testosterone by 9.9 nmol/L, FSH by 4.9 IU/L, LH by 4.8 IU/L, and estradiol by 53.9 pmol/L (all p<0.001). TMSC change was not linked to age, body mass index (BMI), baseline hormones, or treatment duration. Men with primary (n=46) vs. secondary infertility (n=14) demonstrated similar TMSC and hormonal changes.
conclusionsCC was associated with higher TMSC and reproductive hormones. Response was independent of age, BMI, baseline hormones, and duration. Larger, prospective studies are needed to confirm findings and guide candidate selection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.